Spots Global Cancer Trial Database for Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
Official Title: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
Study ID: NCT02102594
Interventions
Study Description
Brief Summary: The aim of this pilot study is to investigate the application of proteasome inhibitor Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with therapy-refractory antibody-mediated autoimmune diseases. The investigators hypothesis is that the proteasome inhibition will lead to reduced antibody titers and improved clinical outcome.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Charite - Universitätsmedizin Berlin, NeuroCure Clinical Research Center, Berlin, , Germany
Charité - Universitätsmedizin Berlin, Internal Medicine / Rheumathology, Berlin, , Germany
Contact Details
Name: Andreas Meisel, Prof. Dr.
Affiliation: Charité - Universitätsmedizin Berlin, NeuroCure Clinical Research Center
Role: PRINCIPAL_INVESTIGATOR
Name: Falk Hiepe, Prof. Dr.
Affiliation: Charité - Universitätsmedizin Berlin, Internal Medicine / Rheumatology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
